Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...
Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in ...
The combination of Gilead Sciences' antibody-drug conjugate, ADC, Trodelvy, sacituzumab govitecan, and the immunotherapy ...
Chinese biopharma Akeso has reported positive overall survival (OS) data for ivonescimab against Merck & Co's Keytruda ...
About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics’ ivonescimab—and the ...
From today, the Australian government will expand Pharmaceutical Benefits Scheme (PBS) access to the drug Keytruda for three additional types of cancer.
Zacks Investment Research on MSN
MRK banks on growing pipeline & new drugs to offset Keytruda LOE
Merck MRK is relying on a growing pipeline and an expanding portfolio of newer medicines, including acquired assets, to ...
The patient support programs earning the strongest marks from physicians, practice-based staff, and patients are not necessarily those offering the most services, but those that most effectively ...
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for ...
Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.
Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...
From today, the Australian government will expand Pharmaceutical Benefit Scheme (PBS) access to the drug Keytruda for three additional types of cancer. This is part of a broader shift away from cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results